

Washington University School of Medicine

Digital Commons@Becker

2020-Current year OA Pubs

Open Access Publications

9-5-2023

ACC/AHA hypertension guidelines and CHA2DS2-VASc up-scoring in patients with atrial fibrillation

Krishna Pundi

Kensey L Gosch

Alexander C Perino

Philip G Jones

Nihar R Desai

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

 Part of the [Medicine and Health Sciences Commons](#)

Please let us know how this document benefits you.

Authors

Krishna Pundi, Kensey L Gosch, Alexander C Perino, Philip G Jones, Nihar R Desai, Thomas M Maddox,
and Mintu Turakhia



Research Letter | Cardiology

ACC/AHA Hypertension Guidelines and CHA₂DS₂-VASc Up-Scoring in Patients With Atrial Fibrillation

Krishna Pundi, MD; Kensey L. Gosch, MS; Alexander C. Perino, MD; Philip G. Jones, MS; Nihar R. Desai, MD, MPH; Thomas M. Maddox, MD, MSc; Mintu Turakhia, MD, MAS

Introduction

The CHA₂DS₂-VASc score identifies patients with atrial fibrillation (AF) who are likely to derive net clinical benefit from oral anticoagulation (OAC).¹ One component of CHA₂DS₂-VASc is hypertension, defined by contemporary clinical practice.¹ The 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension guidelines lowered the blood pressure (BP) threshold to diagnose hypertension from 140/90 to 130/80 mm Hg.² Among nonhypertensive patients with AF, the new definition may result in earlier hypertension diagnoses, CHA₂DS₂-VASc up-scoring, and earlier OAC indications in those with previous scores of 0 or 1.

Methods

We performed a retrospective cohort study of nonhypertensive patients with AF using the National Cardiovascular Data Registry Practice Innovation and Clinical Excellence (PINNACLE) outpatient quality improvement registry (cohort selection diagram in eFigure in Supplement 1).³ The first encounter on or after January 1, 2016, was the index encounter. Informed consent waiver and study authorization were granted by Advarra. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

We used 2 hypertension definitions: Eighth Joint National Committee (JNC 8) hypertension, defined as having 2 or more BP measurements with a systolic pressure of 140 mm Hg or higher and/or diastolic pressure of 90 mm Hg or higher within a 2-year span; or 2017 ACC/AHA hypertension, using BP cutoffs of 130 and 80 mm Hg, correspondingly. The primary outcome was CHA₂DS₂-VASc up-scoring (details of CHA₂DS₂-VASc calculation in eTable in Supplement 1), defined as receiving 1 point for hypertension with 2017 ACC/AHA hypertension but not JNC 8 hypertension, in patients with an initial score of 0 or 1. We used Kaplan-Meier product limit survival estimates to calculate the duration from the first encounter with CHA₂DS₂-VASc up-scoring until (1) JNC 8 hypertension diagnosis, (2) CHA₂DS₂-VASc score of 2 or higher from accumulating different comorbidities or increase in age, or (3) end of follow-up.

Results

The analysis cohort comprised 316 388 patients (mean [SD] age, 68 [15] years; 42% female) with AF and outpatient encounters on or after January 1, 2016 (Table). At the index encounter, 53 920 patients (17.0%) met the 2017 ACC/AHA hypertension definition based on previous BP values, of whom 6420 (11.9%) had an index CHA₂DS₂-VASc score of 0 and 11 451 (21.2%) had a score of 1 (prior to new hypertension diagnosis). At 36 months, 83.5% of patients met the 2017 ACC/AHA hypertension definition, compared with 53.3% with the JNC 8 hypertension definition (Figure). At 36 months, 51.4% of patients with an index CHA₂DS₂-VASc score of 0 had JNC 8 hypertension compared with 86.6% with 2017 ACC/AHA hypertension; in patients with an index CHA₂DS₂-VASc score of 1, 50.0% had JNC 8 hypertension compared with 83.0% with 2017 ACC/AHA hypertension.

+ Supplemental content

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Table. Baseline Characteristics of Nonhypertensive Patients With AF With Outpatient Encounters On or After January 1, 2016


Characteristic	Patients, No. (%) (N = 316 388)
Age, mean (SD), y	68.0 (14.5)
Sex	
Female	134 055 (42.4)
Male	182 333 (57.6)
Race ^a	
Black/African American	9086 (4.3)
White	197 100 (93.0)
Other ^b	5554 (2.6)
Multiracial	192 (0.1)
Insurance	
None	1774 (0.7)
Private	176 120 (71.8)
Medicare	59 320 (24.2)
Medicaid	5794 (2.4)
Other	2390 (1.0)
Height, mean (SD), cm	172.4 (11.0)
Weight, mean (SD), kg	86.1 (23.1)
BMI, mean (SD)	28.9 (6.8)
Heart rate, mean (SD), beats/min	74.0 (15.4)
Blood pressure, mean (SD), mm Hg	
Systolic	122.6 (15.5)
Diastolic	73.1 (10.1)
Diabetes	33 892 (10.7)
Dyslipidemia	96 942 (30.6)
Heart failure	69 620 (22.0)
Stroke/TIA	36 845 (11.6)
Coronary artery disease	90 289 (28.5)
Peripheral vascular disease	21 079 (6.7)
Stroke	28 471 (9.0)
Myocardial infarction	15 157 (4.8)

Abbreviations: AF, atrial fibrillation; BMI, calculated as weight in kilograms divided by height in meters squared; TIA, transient ischemic attack.

^a Self-reported.

^b Includes American Indian or Alaska Native and Asian.

Figure. Kaplan-Meier Estimates of Freedom From New Hypertension Diagnoses by JNC 8 and 2017 ACC/AHA Definitions



At the index encounter, 53 920 patients (17.0%) met the definition for 2017 American College of Cardiology/American Heart Association (ACC/AHA) hypertension. At 36 months, 83.5% of patients met 2017 ACC/AHA hypertension compared with 53.2% with Eighth Report of the Joint National Committee (JNC 8) hypertension.

In the 113 359 patients with a CHA₂DS₂-VASc score of 0 or 1 at the index encounter, 63.1% had up-scoring by 36 months. The mean (SD) duration of up-scoring was 23 (0.2) months and 20 (0.1) months in those with an index score of 0 and 1, accordingly. In up-scored patients with an index score of 0 or 1, 48% and 52% were receiving OAC within 12 months of up-scoring, accordingly.

Discussion

While the definition of hypertension has changed in response to landmark clinical trials,⁴ CHA₂DS₂-VASc was validated using an older hypertension definition¹ with limited ambulatory BP monitoring and higher BP goals for treatment. Now, patients with AF will meet the CHA₂DS₂-VASc threshold for OAC earlier in their disease course. However, it is not known if patients with scores of 1 or 2 using the new hypertension definition have sufficient stroke risk to offset the bleeding risk of OAC and will receive net clinical benefit.⁵

Our study has limitations. PINNACLE cannot incorporate home BP measurements or those from unlinked health care systems. PINNACLE is also an outpatient quality improvement registry not suited to evaluate clinical end points. Our findings support the need to recalibrate AF stroke risk prediction to provide a stronger, contemporary evidence base and incorporate other comorbidities, AF severity and characteristics, and imaging features⁶ to facilitate nuanced patient counseling and shared decision-making.

ARTICLE INFORMATION

Accepted for Publication: August 18, 2023.

Published: September 26, 2023. doi:[10.1001/jamanetworkopen.2023.35722](https://doi.org/10.1001/jamanetworkopen.2023.35722)

Open Access: This is an open access article distributed under the terms of the [CC-BY License](https://creativecommons.org/licenses/by/4.0/). © 2023 Pundi K et al. *JAMA Network Open*.

Corresponding Author: Mintu Turakhia, MD, MAS, Department of Medicine, Stanford University School of Medicine, 3801 Miranda Ave, 111C, Palo Alto, CA 94304 (mintu@stanford.edu).

Author Affiliations: Department of Medicine, Stanford University School of Medicine, Stanford, California (Pundi, Perino, Turakhia); St Luke's Mid America Heart Institute, Kansas City, Missouri (Gosch, Jones); Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut (Desai); Division of Cardiology, Washington University School of Medicine, St Louis, Missouri (Maddox).

Author Contributions: Drs Pundi and Turakhia had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Pundi, Perino, Turakhia.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Pundi, Perino.

Critical review of the manuscript for important intellectual content: Gosch, Jones, Desai.

Statistical analysis: Pundi, Gosch, Jones, Turakhia.

Obtained funding: Pundi, Turakhia.

Administrative, technical, or material support: Desai, Turakhia.

Supervision: Pundi, Perino, Turakhia.

Conflict of Interest Disclosures: Dr Pundi reported grants from the American Heart Association and the American College of Cardiology and personal fees from Evidently and IOOPlus. Dr Perino reported grants from the American Heart Association and Bristol Myers Squibb/Pfizer and personal fees from Pfizer and Bristol Myers Squibb. Dr Desai reported grants from Amgen, AstraZeneca, Boehringer Ingelheim, Cytokinetics, and Vifor and personal fees from Bayer, Bristol Myers Squibb, Merck, Novartis, and SC Pharmaceuticals outside the submitted work. Dr Turakhia reported employment from iRhythm Technologies; equity from AliveCor, Connect America, Evidently, and Forward; grants from US Food and Drug Administration, American Heart Association, Bayer, Sanofi, Gilead, and Bristol Myers Squibb; and personal fees from Pfizer and *JAMA Cardiology* (prior Associate Editor) outside the submitted work. No other disclosures were reported.

Funding/Support: This research was supported by the American College of Cardiology Foundation's National Cardiovascular Data Registry (NCDR) (Washington, DC).

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The views expressed in this article represent those of the authors, and do not necessarily represent the official views of the NCDR or its associated professional societies identified at CVQuality.ACC.org.

Data Sharing Statement: See [Supplement 2](#).

Additional Contributions: Quality checks and analyses of the data have been performed at Saint Luke's Mid America Heart Institute, the primary analytical center for the PINNACLE Registry. We acknowledge Natasha Din, MD, MAS (Veterans Affairs Palo Alto Health Care System, Palo Alto, CA), for her contributions to this research and in preparation of the manuscript. Dr Din did not receive any compensation for these contributions.

REFERENCES

1. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. *Chest*. 2010;137(2):263-272. doi:10.1378/chest.09-1584
2. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2018;138(17):e426-e483. doi:10.1161/CIR.0000000000000597
3. Messenger JC, Ho KKL, Young CH, et al; NCDR Science and Quality Oversight Committee Data Quality Workgroup. The National Cardiovascular Data Registry (NCDR) data quality brief: the NCDR Data Quality Program in 2012. *J Am Coll Cardiol*. 2012;60(16):1484-1488. doi:10.1016/j.jacc.2012.07.020
4. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311(5):507-520. doi:10.1001/jama.2013.284427
5. Eckman MH, Singer DE, Rosand J, Greenberg SM. Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2011;4(1):14-21. doi:10.1161/CIRCOUTCOMES.110.958108
6. Turakhia MP. It's time to rethink (and retreat) our framework for stroke prevention in atrial fibrillation. *JAMA Cardiol*. 2021;6(12):1370. doi:10.1001/jamacardio.2021.3709

SUPPLEMENT 1.

eTable. CHA₂DS₂-VASc Score Definitions

eFigure. Cohort Selection Diagram

SUPPLEMENT 2.

Data Sharing Statement